Merck has announced its intention to acquire Terns Pharmaceuticals for approximately $6.7 billion, according to statnews.com. The deal values Terns at $53 per share, representing a 6% premium over its Tuesday closing price. This acquisition is aimed at strengthening Merck's cancer drug pipeline as it prepares for the impending patent expiration of Keytruda, its blockbuster immunotherapy treatment.
Key Takeaways
Merck is acquiring Terns Pharmaceuticals for $6.7 billion to bolster its cancer drug portfolio as it prepares for Keytruda's patent expiration in 2028. This deal values Terns at $53 per share, a 6% premium over its previous closing price, and follows significant stock growth driven by the potential of TERN-701, a leukemia treatment currently in early clinical studies.
Terns' stock has seen a remarkable six-fold increase over the past six months due to the promising potential of TERN-701, an experimental leukemia drug. The acquisition is expected to close in the second quarter and will significantly enhance Merck's oncology portfolio as it faces increasing competition with Keytruda's patent set to expire in 2028.
Merck CEO Robert Davis emphasized that Terns' experimental pill could be a significant growth driver over the next decade, despite being in early clinical studies. The company is betting on initial promising data to translate into successful larger trials. This acquisition follows Merck's recent dealmaking spree, including the purchase of Cidara Therapeutics and Verona Pharma last year.
Analysts view this acquisition as strategically sound for Merck, demonstrating its commitment to pursuing differentiated oncology assets early. The company remains opportunistic in its approach, looking for further deals in areas such as immunology, cardiometabolic health, vaccines, and ophthalmology. This move is part of a broader strategy to reduce dependence on Keytruda, which currently accounts for nearly half of Merck's sales.
How this summary was created
This summary synthesizes reporting from 4 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.